Leerink Partnrs Predicts Weaker Earnings for Beta Bionics

Beta Bionics, Inc. (NASDAQ:BBNX) – Research analysts at Leerink Partnrs lowered their Q1 2025 earnings estimates for Beta Bionics in a research report issued to clients and investors on Wednesday, March 26th. Leerink Partnrs analyst M. Kratky now anticipates that the company will post earnings per share of ($0.51) for the quarter, down from their prior forecast of ($0.50). Leerink Partnrs has a “Strong-Buy” rating on the stock. Leerink Partnrs also issued estimates for Beta Bionics’ Q3 2025 earnings at ($0.42) EPS, Q4 2025 earnings at ($0.39) EPS, FY2025 earnings at ($1.83) EPS and FY2027 earnings at ($2.27) EPS.

Beta Bionics (NASDAQ:BBNX) last issued its quarterly earnings data on Tuesday, March 25th. The company reported ($1.82) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.42) by ($1.40). The company had revenue of $20.44 million during the quarter, compared to analyst estimates of $20.01 million.

Several other equities analysts have also recently issued reports on BBNX. Piper Sandler assumed coverage on shares of Beta Bionics in a research report on Monday, February 24th. They issued an “overweight” rating and a $26.00 price target for the company. LADENBURG THALM/SH SH initiated coverage on Beta Bionics in a report on Thursday, February 20th. They issued a “neutral” rating and a $20.00 price objective for the company. Stifel Nicolaus began coverage on Beta Bionics in a report on Monday, February 24th. They set a “buy” rating and a $25.00 target price on the stock. Lake Street Capital began coverage on Beta Bionics in a research report on Monday, February 24th. They issued a “buy” rating and a $30.00 price target on the stock. Finally, Baird R W upgraded Beta Bionics to a “hold” rating in a research report on Thursday, February 20th. Three research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $24.83.

Beta Bionics Price Performance

Beta Bionics stock opened at $11.71 on Friday. The firm has a 50 day moving average price of $18.76. Beta Bionics has a 1 year low of $11.43 and a 1 year high of $24.50.

Insider Activity

In other Beta Bionics news, insider Mike Mensinger bought 33,350 shares of the stock in a transaction on Friday, January 31st. The stock was acquired at an average cost of $17.00 per share, for a total transaction of $566,950.00. Following the completion of the acquisition, the insider now owns 59,019 shares in the company, valued at $1,003,323. This trade represents a 129.92 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available at this link. Also, major shareholder Hadley Harbor Aggre Wellington purchased 1,000,000 shares of the company’s stock in a transaction on Friday, January 31st. The stock was acquired at an average cost of $17.00 per share, for a total transaction of $17,000,000.00. Following the completion of the purchase, the insider now owns 3,901,599 shares of the company’s stock, valued at approximately $66,327,183. This trade represents a 34.46 % increase in their position. The disclosure for this purchase can be found here.

Beta Bionics Company Profile

Beta Bionics, Inc is a commercial-stage medical device company. It engages in the design, development, and commercialization of solutions for insulin-requiring people with diabetes. The company was founded by Edward R. Damiano on October 21, 2015 and is headquartered in Irvine, CA.